JP5755657B2 - 感受性バイオマーカーとして熱ショックタンパク質７２を用いる、急性腎障害を検出するための診断方法 - Google Patents
感受性バイオマーカーとして熱ショックタンパク質７２を用いる、急性腎障害を検出するための診断方法 Download PDFInfo
- Publication number
- JP5755657B2 JP5755657B2 JP2012541040A JP2012541040A JP5755657B2 JP 5755657 B2 JP5755657 B2 JP 5755657B2 JP 2012541040 A JP2012541040 A JP 2012541040A JP 2012541040 A JP2012541040 A JP 2012541040A JP 5755657 B2 JP5755657 B2 JP 5755657B2
- Authority
- JP
- Japan
- Prior art keywords
- hsp72
- urine
- aki
- minutes
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 title claims description 76
- 208000009304 Acute Kidney Injury Diseases 0.000 title claims description 49
- 208000033626 Renal failure acute Diseases 0.000 title claims description 49
- 201000011040 acute kidney failure Diseases 0.000 title claims description 49
- 239000000090 biomarker Substances 0.000 title description 30
- 238000002405 diagnostic procedure Methods 0.000 title description 3
- 210000002700 urine Anatomy 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 210000003734 kidney Anatomy 0.000 claims description 25
- 238000001514 detection method Methods 0.000 claims description 20
- 230000006378 damage Effects 0.000 claims description 19
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 230000001965 increasing effect Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 40
- 241000700159 Rattus Species 0.000 description 31
- 208000028867 ischemia Diseases 0.000 description 26
- 229940109239 creatinine Drugs 0.000 description 20
- 238000001262 western blot Methods 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 230000002485 urinary effect Effects 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 14
- 210000005239 tubule Anatomy 0.000 description 12
- 238000011002 quantification Methods 0.000 description 10
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 9
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 9
- 206010061481 Renal injury Diseases 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000002146 bilateral effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 5
- 206010038540 Renal tubular necrosis Diseases 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- 238000007675 cardiac surgery Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000008327 renal blood flow Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000007495 abnormal renal function Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 208000037978 tubular injury Diseases 0.000 description 2
- 230000010024 tubular injury Effects 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010036652 HSC70 Heat-Shock Proteins Proteins 0.000 description 1
- 102000012215 HSC70 Heat-Shock Proteins Human genes 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 231100000856 decreased creatinine clearance Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- -1 mHsp95 Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXMX/A/2009/012633 | 2009-11-23 | ||
| MX2009012633A MX2009012633A (es) | 2009-11-23 | 2009-11-23 | Metodo de diagnostico para detectar la lesion renal aguda a traves del uso de la proteina de choque termico de 72 kda como un biomarcador sensible. |
| PCT/MX2010/000138 WO2011062469A2 (es) | 2009-11-23 | 2010-11-23 | Método de diagnóstico para detectar la lesión renal aguda a través del uso de la proteína de choque térmico de 72 kda como un biomarcador sensible |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511735A JP2013511735A (ja) | 2013-04-04 |
| JP2013511735A5 JP2013511735A5 (enExample) | 2014-01-16 |
| JP5755657B2 true JP5755657B2 (ja) | 2015-07-29 |
Family
ID=44060228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541040A Expired - Fee Related JP5755657B2 (ja) | 2009-11-23 | 2010-11-23 | 感受性バイオマーカーとして熱ショックタンパク質７２を用いる、急性腎障害を検出するための診断方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20130065239A1 (enExample) |
| EP (1) | EP2506016B1 (enExample) |
| JP (1) | JP5755657B2 (enExample) |
| CN (1) | CN102762985B (enExample) |
| CA (1) | CA2781754C (enExample) |
| ES (1) | ES2549610T3 (enExample) |
| MX (1) | MX2009012633A (enExample) |
| WO (1) | WO2011062469A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011149962A1 (en) | 2010-05-24 | 2011-12-01 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| WO2011162821A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| ES2721907T3 (es) | 2011-08-26 | 2019-08-06 | Astute Medical Inc | Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal |
| CN102879584A (zh) * | 2012-09-26 | 2013-01-16 | 中国人民解放军军事医学科学院基础医学研究所 | 一种人血液hsp70抗体胶体金标检测试纸条及其制备方法 |
| WO2014081980A2 (en) | 2012-11-21 | 2014-05-30 | The Trustees Of Columbia University In The City Of New York | Mutant ngal proteins and uses thereof |
| KR101468047B1 (ko) * | 2013-01-16 | 2014-12-02 | 고려대학교 산학협력단 | 열충격단백질군의 mRNA 발현 양상 분석을 통한 사인 추정방법 |
| US11346846B2 (en) | 2017-02-06 | 2022-05-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN107045594B (zh) * | 2017-04-25 | 2018-06-26 | 吉林大学 | 一种脊柱损伤测量中x射线标志物的数字化系统 |
| CN109754394B (zh) * | 2018-12-28 | 2021-02-23 | 上海联影智能医疗科技有限公司 | 三维医学图像处理装置及方法 |
| WO2020125806A1 (en) | 2018-12-17 | 2020-06-25 | Shanghai United Imaging Intelligence Co., Ltd. | Systems and methods for image segmentation |
| CN111007255A (zh) * | 2019-12-10 | 2020-04-14 | 江苏三联生物工程有限公司 | 一种用于肾损伤标志物检测的蛋白芯片及其制备方法 |
| CN116449024A (zh) * | 2023-04-13 | 2023-07-18 | 武汉市第三医院 | Saa1作为生物标志物在预测或诊断急性肾损伤中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4035591B2 (ja) * | 2003-01-24 | 2008-01-23 | 株式会社三重ティーエルオー | 血管障害病態改善剤 |
| US7833732B2 (en) * | 2005-07-21 | 2010-11-16 | The John Hopkins University | Acute renal injury |
-
2009
- 2009-11-23 MX MX2009012633A patent/MX2009012633A/es active IP Right Grant
-
2010
- 2010-11-23 ES ES10831836.1T patent/ES2549610T3/es active Active
- 2010-11-23 JP JP2012541040A patent/JP5755657B2/ja not_active Expired - Fee Related
- 2010-11-23 WO PCT/MX2010/000138 patent/WO2011062469A2/es not_active Ceased
- 2010-11-23 EP EP10831836.1A patent/EP2506016B1/en not_active Not-in-force
- 2010-11-23 CA CA2781754A patent/CA2781754C/en not_active Expired - Fee Related
- 2010-11-23 US US13/511,633 patent/US20130065239A1/en not_active Abandoned
- 2010-11-23 CN CN201080062143.5A patent/CN102762985B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011062469A3 (es) | 2011-11-24 |
| WO2011062469A2 (es) | 2011-05-26 |
| EP2506016A4 (en) | 2013-01-23 |
| WO2011062469A8 (es) | 2012-01-12 |
| CN102762985B (zh) | 2015-06-17 |
| CA2781754A1 (en) | 2011-05-26 |
| CN102762985A (zh) | 2012-10-31 |
| JP2013511735A (ja) | 2013-04-04 |
| US20130065239A1 (en) | 2013-03-14 |
| MX2009012633A (es) | 2011-05-24 |
| EP2506016A2 (en) | 2012-10-03 |
| CA2781754C (en) | 2019-09-03 |
| ES2549610T3 (es) | 2015-10-29 |
| EP2506016B1 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5755657B2 (ja) | 感受性バイオマーカーとして熱ショックタンパク質７２を用いる、急性腎障害を検出するための診断方法 | |
| JP5054525B2 (ja) | 腎疾患および腎損傷の早期発見のための方法 | |
| EP2083270B1 (en) | A method and kit for detecting the early onset of renal tubular cell injury | |
| US20100184110A1 (en) | Predictive diagnostics for kidney disease | |
| WO2007124419A1 (en) | Method and kit for the early detection of impaired renal status | |
| Cruz et al. | Role of biomarkers in the diagnosis and management of cardio-renal syndromes | |
| TWI822802B (zh) | 腎病變蛋白生物標記及其應用 | |
| Skowron et al. | Urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, uromodulin, and cystatin C concentrations in an experimental rat model of ascending acute kidney injury induced by pyelonephritis | |
| JP4949473B2 (ja) | 肝機能を評価するためのバイオマーカー | |
| JP2010500535A (ja) | 重大な腎損傷を除外するための診断検査 | |
| EP2882767B1 (en) | Evaluating renal injury using hyaluronic acid | |
| US20240302385A1 (en) | Biomarker for detecting tubulointerstitial disorder and use thereof | |
| Dissayabutra et al. | Increased protein excretion, including albumin by children of patients with urolithiasis | |
| WO2024225457A1 (ja) | ＩｇＡ腎症の判定方法 | |
| HK1161912B (en) | A method and kit for detecting the early onset of renal tubular cell injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131122 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131122 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5755657 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |